Ten-year survival trends of neovascular age-related macular degeneration at first presentation.
CONCLUSIONS: The chronicity of nAMD disease and its management highlights the importance of long-term visual prognosis. Our analyses suggest that one in five patients will retain good vision (BCVA ≥70 ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF treatment; yet, one in two patients will have good vision in their better-seeing eye. Moreover, our data suggest that early treatment of nAMD is associated with better visual outcomes.
PMID: 33011683 [PubMed - as supplied by publisher]
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Arpa C, Khalid H, Chandra S, Wagner S, Fasler K, Faes L, Pooprasert P, Chopra R, Moraes G, Balaskas K, Keane PA, Sivaprasad S, Fu DJ Tags: Br J Ophthalmol Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Eyes | Lucentis | Opthalmology | Ranibizumab Injection | Study | UK Health | Vitamin A